Publication: 3494

Publication: 3494

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Am J Hematol vol 96 (12) 1595-1603

Year:: 2021
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Preliminary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 11

Parents:: 2388 3755 3794
Children:: None

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Celgene/BMS
Grants:: U10CA180821, U10CA180882, UG1CA233191, UG1CA233290, UG1CA233331, UG1CA233373

Corr. Author:
Authors:: Peter M. Voorhees Vera J. Suman Sascha A. Tuchman Jacob P. Laubach Hani Hassoun Yvonne A. Efebera Flora Mulkey Misty Bova-Solem Katelyn Santo Destin Carlisle Philip L. McCarthy Paul G. Richardson

Networks:: LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-NY158, NC002, OH008

Study: Alliance-A061202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 1/2

Keywords:: Article